Zobrazeno 1 - 10
of 1 306
pro vyhledávání: '"CDK4/6 inhibitors"'
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-8 (2024)
Abstract Objective This study used real-world observational data to compare profiles of patients receiving different first-line treatment for hormone receptor positive (ER+), HER2 negative, metastatic breast cancer (MBC): CDK4/6 inhibitors (CDK4/6i)
Externí odkaz:
https://doaj.org/article/85c8f2c797de414faac06f0916ec2555
Autor:
Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 13, Pp 501-512 (2024)
Hikmat Abdel-Razeq,1,2 Baha Sharaf,1 Suhaib Khater,1 Huda Jafar Baidoun,2 Hira Bani Hani,1 Ayat Taqash,3 Osama El Khatib,1 Sarah Edaily,1 Mahmoud Abunasser,1 Faris Tamimi,1 Yosra Nabeel Al-Masri,1 Tamer Moh’d Waleed Al-Batsh,1 Anas Zayed,1 Tala Gha
Externí odkaz:
https://doaj.org/article/a11cfe5e6ffa41b2b2eca6ea7b3bc8f7
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 517-527 (2024)
Kaitlyn O’Keefe, Neelam V Desai, Antoinette R Tan Department of Solid Tumor and Investigational Therapeutics, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USACorrespondence: Antoinette R Tan, Depa
Externí odkaz:
https://doaj.org/article/be056c6ba056409ea620b5f2995cf652
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 395-418 (2024)
Abstract Introduction Limited awareness exists regarding real-world data (RWD) for palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in populations from certain
Externí odkaz:
https://doaj.org/article/d3d5c5d38dd54e5fb401805a467c3fba
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Does incorporating Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into endocrine therapy (ET) effectively enhance survival outcomes, notably overall survival (OS), among individuals with hormone receptor-positive (HR+), human epi
Externí odkaz:
https://doaj.org/article/d64949f51d5946d6bc944246b75adc5d
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 182-189 (2024)
The classification of breast cancer (BC) by immunohistochemical phenotypes is widely used in routine clinical practice. However, the genetic profile of the tumor does not always correspond to the pathomorphological one, which can significantly affect
Externí odkaz:
https://doaj.org/article/9bd059acb1804b48b14f790646bef706
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background The current study evaluated the disease burden, health care resource utilization and analyzed the cost burden due to events of special interest among patients with breast cancer (BC) diagnosed and treated in Dubai, United Arab Emi
Externí odkaz:
https://doaj.org/article/367fee60585e4f269491fc783c978680
Autor:
I. V. Kolyadina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 1, Pp 89-103 (2024)
This review presents the evolution of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer, describes late relapse phenomenon, provides clinical rationale for escalation of treatment, analyzes the key stages of the metas
Externí odkaz:
https://doaj.org/article/9e0dc10a36ac41af969d515ba1adb06b
Autor:
Yingshu Cui, Yi Li, Yuanyuan Xu, Xinxin Liu, Xiaofeng Kang, Junwen Zhu, Shan Long, Yuchen Han, Chunyuan Xue, Zhijia Sun, Yimeng Du, Jia Hu, Lu Pan, Feifan Zhou, Xiaojie Xu, Xiaosong Li
Publikováno v:
Redox Biology, Vol 76, Iss , Pp 103304- (2024)
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) can significantly extend tumor response in patients with metastatic luminal A breast cancer, yet intrinsic and acquired resistance remains a prevalent issue. Understanding the molecular f
Externí odkaz:
https://doaj.org/article/6cdfbac978f44be098e3d989c45232c6
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe combination of cyclin-dependent kinases 4/6 (CDK4/6) inhibitors and endocrine therapy is the standard treatment for patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer. However, the role of CDK4/6
Externí odkaz:
https://doaj.org/article/19576f8d9d9f4e2da5d238c2075fd9a3